Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant abiraterone with or without docetaxel before radical prostatectomy for locally advanced prostate cancer
ChiCTR2100045627Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Jan 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of abiraterone and docetaxel in prostate cancer (PCa) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Post-operative biochemical progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
abirateronedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2100045627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045627.